SINTX Technologies (SINT) announced the sale of its wholly-owned subsidiary, Technology Assessment and Transfer, to Tethon Corporation. This transaction marks a significant step in SINTX’s ongoing transformation, allowing the Company to sharpen its focus on high-growth opportunities in the medical device sector while improving its financial position and operational efficiency. The divestment aligns with SINTX’s refined strategy to accelerate innovation in the healthcare space. With this sale, SINTX is streamlining its operations to concentrate on commercializing bioceramic technologies that have the potential to improve patient outcomes and enhance the performance of medical implants and devices. The sale of TA&T also reduces corporate liabilities by $750,000 and lowers annual operating expenses by more than $1.7M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SINT:
- 3 Penny Stocks to Watch Now, 2/20/25
- Sintx Technologies awarded patent on silicon nitride material by USPTO